Cargando…

Cupriavidus necator-Produced Polyhydroxybutyrate/Eudragit FS Hybrid Nanoparticles Mitigates Ulcerative Colitis via Colon-Targeted Delivery of Cyclosporine A

Polyhydroxybutyrate (PHB) has emerged as a novel material for replacing various plastics used in the medical field. However, its application as a drug-delivery carrier for colitis-targeted delivery has not been explored. In this study, we used biosynthesized PHB combined with Eudragit FS (EFS) and c...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Juho, Saparbayeva, Aruzhan, Hlaing, Shwe Phyu, Kwak, Dongmin, Kim, Hyunwoo, Kim, Jihyun, Lee, Eun Hee, Yoo, Jin-Wook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9787777/
https://www.ncbi.nlm.nih.gov/pubmed/36559305
http://dx.doi.org/10.3390/pharmaceutics14122811
_version_ 1784858594267627520
author Lee, Juho
Saparbayeva, Aruzhan
Hlaing, Shwe Phyu
Kwak, Dongmin
Kim, Hyunwoo
Kim, Jihyun
Lee, Eun Hee
Yoo, Jin-Wook
author_facet Lee, Juho
Saparbayeva, Aruzhan
Hlaing, Shwe Phyu
Kwak, Dongmin
Kim, Hyunwoo
Kim, Jihyun
Lee, Eun Hee
Yoo, Jin-Wook
author_sort Lee, Juho
collection PubMed
description Polyhydroxybutyrate (PHB) has emerged as a novel material for replacing various plastics used in the medical field. However, its application as a drug-delivery carrier for colitis-targeted delivery has not been explored. In this study, we used biosynthesized PHB combined with Eudragit FS (EFS) and cyclosporine A (CSA) to develop pH-responsive controlled CSA-releasing nanoparticles (CSA-PENPs) for colitis-targeted drug delivery and demonstrated its enhanced therapeutic efficacy in a dextran sulfate sodium (DSS)-induced murine colitis model. PHB was successfully biosynthesized in the bacterium Cupriavidus necator, as demonstrated by (1)H-NMR and FT-IR analyses. CSA-PENPs were fabricated via the oil-in-water emulsion solvent evaporation method. Owing to the potent pH-responsive and sustained drug release properties provided by PHB and EFS, CSA-PENPs could deliver a sufficient amount of CSA to inflamed tissues in the distal colon; in contrast, CSA-loaded EFS nanoparticles displayed premature burst release before reaching the target site. Due to enhanced CSA delivery to colitis tissues, CSA-PENPs exhibited potent anti-inflammatory effects in the DSS-induced murine colitis model. Overall, CSA-PENPs could be a promising drug-delivery system for treating ulcerative colitis.
format Online
Article
Text
id pubmed-9787777
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97877772022-12-24 Cupriavidus necator-Produced Polyhydroxybutyrate/Eudragit FS Hybrid Nanoparticles Mitigates Ulcerative Colitis via Colon-Targeted Delivery of Cyclosporine A Lee, Juho Saparbayeva, Aruzhan Hlaing, Shwe Phyu Kwak, Dongmin Kim, Hyunwoo Kim, Jihyun Lee, Eun Hee Yoo, Jin-Wook Pharmaceutics Article Polyhydroxybutyrate (PHB) has emerged as a novel material for replacing various plastics used in the medical field. However, its application as a drug-delivery carrier for colitis-targeted delivery has not been explored. In this study, we used biosynthesized PHB combined with Eudragit FS (EFS) and cyclosporine A (CSA) to develop pH-responsive controlled CSA-releasing nanoparticles (CSA-PENPs) for colitis-targeted drug delivery and demonstrated its enhanced therapeutic efficacy in a dextran sulfate sodium (DSS)-induced murine colitis model. PHB was successfully biosynthesized in the bacterium Cupriavidus necator, as demonstrated by (1)H-NMR and FT-IR analyses. CSA-PENPs were fabricated via the oil-in-water emulsion solvent evaporation method. Owing to the potent pH-responsive and sustained drug release properties provided by PHB and EFS, CSA-PENPs could deliver a sufficient amount of CSA to inflamed tissues in the distal colon; in contrast, CSA-loaded EFS nanoparticles displayed premature burst release before reaching the target site. Due to enhanced CSA delivery to colitis tissues, CSA-PENPs exhibited potent anti-inflammatory effects in the DSS-induced murine colitis model. Overall, CSA-PENPs could be a promising drug-delivery system for treating ulcerative colitis. MDPI 2022-12-15 /pmc/articles/PMC9787777/ /pubmed/36559305 http://dx.doi.org/10.3390/pharmaceutics14122811 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lee, Juho
Saparbayeva, Aruzhan
Hlaing, Shwe Phyu
Kwak, Dongmin
Kim, Hyunwoo
Kim, Jihyun
Lee, Eun Hee
Yoo, Jin-Wook
Cupriavidus necator-Produced Polyhydroxybutyrate/Eudragit FS Hybrid Nanoparticles Mitigates Ulcerative Colitis via Colon-Targeted Delivery of Cyclosporine A
title Cupriavidus necator-Produced Polyhydroxybutyrate/Eudragit FS Hybrid Nanoparticles Mitigates Ulcerative Colitis via Colon-Targeted Delivery of Cyclosporine A
title_full Cupriavidus necator-Produced Polyhydroxybutyrate/Eudragit FS Hybrid Nanoparticles Mitigates Ulcerative Colitis via Colon-Targeted Delivery of Cyclosporine A
title_fullStr Cupriavidus necator-Produced Polyhydroxybutyrate/Eudragit FS Hybrid Nanoparticles Mitigates Ulcerative Colitis via Colon-Targeted Delivery of Cyclosporine A
title_full_unstemmed Cupriavidus necator-Produced Polyhydroxybutyrate/Eudragit FS Hybrid Nanoparticles Mitigates Ulcerative Colitis via Colon-Targeted Delivery of Cyclosporine A
title_short Cupriavidus necator-Produced Polyhydroxybutyrate/Eudragit FS Hybrid Nanoparticles Mitigates Ulcerative Colitis via Colon-Targeted Delivery of Cyclosporine A
title_sort cupriavidus necator-produced polyhydroxybutyrate/eudragit fs hybrid nanoparticles mitigates ulcerative colitis via colon-targeted delivery of cyclosporine a
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9787777/
https://www.ncbi.nlm.nih.gov/pubmed/36559305
http://dx.doi.org/10.3390/pharmaceutics14122811
work_keys_str_mv AT leejuho cupriavidusnecatorproducedpolyhydroxybutyrateeudragitfshybridnanoparticlesmitigatesulcerativecolitisviacolontargeteddeliveryofcyclosporinea
AT saparbayevaaruzhan cupriavidusnecatorproducedpolyhydroxybutyrateeudragitfshybridnanoparticlesmitigatesulcerativecolitisviacolontargeteddeliveryofcyclosporinea
AT hlaingshwephyu cupriavidusnecatorproducedpolyhydroxybutyrateeudragitfshybridnanoparticlesmitigatesulcerativecolitisviacolontargeteddeliveryofcyclosporinea
AT kwakdongmin cupriavidusnecatorproducedpolyhydroxybutyrateeudragitfshybridnanoparticlesmitigatesulcerativecolitisviacolontargeteddeliveryofcyclosporinea
AT kimhyunwoo cupriavidusnecatorproducedpolyhydroxybutyrateeudragitfshybridnanoparticlesmitigatesulcerativecolitisviacolontargeteddeliveryofcyclosporinea
AT kimjihyun cupriavidusnecatorproducedpolyhydroxybutyrateeudragitfshybridnanoparticlesmitigatesulcerativecolitisviacolontargeteddeliveryofcyclosporinea
AT leeeunhee cupriavidusnecatorproducedpolyhydroxybutyrateeudragitfshybridnanoparticlesmitigatesulcerativecolitisviacolontargeteddeliveryofcyclosporinea
AT yoojinwook cupriavidusnecatorproducedpolyhydroxybutyrateeudragitfshybridnanoparticlesmitigatesulcerativecolitisviacolontargeteddeliveryofcyclosporinea